Development of resistance to the lowering of plasma free fatty acids induced by pyrazole derivates.
D000273:Adipose Tissue / Q000187:drug effects*; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D004336:Drug Antagonism; D005227:Fatty Acids / Q000097:blood*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005989:Glycerides / Q000097:blood; D008099:Liver / Q000187:drug effects; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D012965:Sodium Chloride; D013806:Theophylline / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood
D005227:Fatty Acids; D005230:Fatty Acids, Nonesterified; D005989:Glycerides; D011720:Pyrazoles; D014280:Triglycerides; D012965:Sodium Chloride; D000324:Adrenocorticotropic Hormone; D013806:Theophylline; D009638:Norepinephrine